查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030年全球上呼吸道疾病治疗市场
市场调查报告书
商品编码
1351035

2023-2030年全球上呼吸道疾病治疗市场

Global Upper Respiratory Tract Disease Treatment Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

预计在预测期内（2023-2030年），全球上呼吸道疾病治疗市场将以3.6%的复合年增长率成长。上呼吸道感染 (URTI) 是一种疾病，是由涉及人的上呼吸道（如鼻子、鼻窦、咽或喉）的急性感染引起的。感染常见包括鼻塞、喉咙痛、扁桃体炎、咽炎、喉炎、中耳炎和普通感冒。可以使用多种药物来治疗这种疾病，针对细菌和病毒等致病病原体。越来越多的患有气喘、充血性心臟衰竭和慢性阻塞性肺病的成年人患呼吸道合胞病毒感染的风险更高，导致市场成长。根据美国公共科学图书馆计算生物学的一项研究，URTD是由多种细菌和病毒引起的，感染的情况可以从轻度感冒到危及生命的肺炎。作为最常见的疾病之一，2019 年 URTI 的全球负担估计为 172 亿人。儘管大多数感染 URTI 的人表现出轻微症状，但仅在美国，非流感相关病毒性 URTI 的经济负担估计高达 225 亿美元，并且估计有 20 亿美元用于 URTI 的非处方治疗。

细分市场前景

全球上呼吸道疾病治疗市场按类别、治疗方法和药物类别进行细分。根据类别，市场分为非处方药和处方药。根据治疗方法，市场分为局部治疗、止咳药、鼻减充血剂等。此外，依药物类别，市场分为非类固醇抗发炎药、抗生素等。其中，非处方药细分市场预计将占据相当大的市场份额，因为它无需处方即可轻鬆获得，并且可以有效治疗

感染或细菌性疾病。由于上呼吸道感染以及治疗这些感染的非处方药物的需求不断增加，医师的家访次数也有所增加。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • F. Hoffmann-La Roche Ltd
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Pfizer Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Teva Pharmaceutical Industries Ltd.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 全球上呼吸道疾病治疗市场依类别
    • 场外交易
    • 处方
  • 按治疗分類的全球上呼吸道疾病治疗市场
    • 局部治疗
    • 止咳
    • 鼻减充血剂
    • 其他（抗组织胺、癒创甘油醚和色甘酸）
  • 按药物类别分類的全球上呼吸道疾病治疗市场
    • 非类固醇抗发炎药
    • 抗生素
    • 其他（布洛芬）

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Alcon, Inc.
  • AstraZeneca Plc
  • Cipla Limited
  • CSL Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Lupin Limited
  • Market positioning of vendors
  • Merck & Co., Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Sandoz, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
Product Code: OMR2027636

Title: Global Upper Respiratory Tract Disease Treatment Market Size, Share & Trends Analysis Report by Category (OTC and Prescription), by treatment (topical treatment, cough suppressant, nasal decongestant and other), and by drug class (NSAID, antibiotics and others),Forecast Period (2023-2030).

The global upper respiratory tract disease treatment market is anticipated to grow at a CAGR of 3.6% during the forecast period (2023-2030). upper respiratory tract infection (URTI) is an illness, which is the result of an acute infection involving a person's upper respiratory tract like the nose, sinuses, pharynx, or larynx. The infection commonly includes nasal obstruction, sore throat, tonsillitis, pharyngitis, laryngitis, otitis media, and the common cold. This can be treated using various drugs, targeting disease-causing pathogens like bacteria and viruses. Increasing number of Adults with asthma, congestive heart failure, and COPD are at higher risk of suffering from respiratory syncytial virus infection lead to the growth of the market. According to a study of plos computing biology US, URTD caused by a variety of bacteria and viruses, and the infection can vary from a mild cold to life-threatening pneumonia. Being one of the most common diseases, the global burden of URTI in 2019 is estimated to be 17.2 billion. Although a majority of individuals contracting URTIs present mild symptoms, the estimated economic burden of non-influenza related viral URTIs in the United States alone is estimated to be 22.5 billion USD and an estimated $2 billion is spent on over-the-counter treatments for URTIs.

Segmental Outlook

The global upper respiratory tract disease treatment market is segmented on the category, treatment, and drug class. Based on the category, the market is sub-segmented into OTC and Prescription. Based on the treatment, the market is sub-segmented into topical treatment, cough suppressant, nasal decongestant and other. Further, on the basis of drug class, the market is sub-segmented into NSAID, antibiotics and others. Among the category, the OTC sub-segment is anticipated to hold a considerable share of the market owing to its easy availability without any prescription and it is effective in treating

Inflectional or bacterial diseases. Also increase in the home visits by physicians due to upper respiratory tract infections and escalating demand for over the counter medicines to treat these infections.

The Antibiotic Sub-Segment is Anticipated to Hold a Considerable Share of the Global Upper Respiratory Tract Disease Treatment Market

Among the drug class, the antibiotic sub-segment is expected to hold a considerable share of the global upper respiratory tract disease market. The segmental growth is attributed to the growing cases of upper respiratory tract disease and lack of availability and affordability of doctors and proper medical prescription in many countries such as Africa, Sri Lanka, and Pakistan. Which lead to increase in demand for antibiotics owing to its easy availability of antibiotics to treat upper respiratory tract infections and their symptoms will drive the upper respiratory tract infection treatment market.

Regional Outlook

The global Upper Respiratory Tract Disease Treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia pacific is anticipated to hold a prominent share of the market across the globe, owing to rise in demand due to increasing case of bacterial and viral diseases in the countries like china, India and Indonesia.

The North America Region is Expected to Grow at a Significant CAGR in the Global Upper Respiratory Tract Disease Treatment Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to increasing prevalence of upper respiratory tract infections in the region due to sudden climate changes and increasing consumption of cigarette. Owing to Increase in demand for Cough suppressants, nasal decongestants, and nasal washes. According to a report of national library of medicine US, in September 2022, chronic diseases associated with cigarette smoking include respiratory and cardiovascular diseases, cancers, and diabetes. An estimated 16 million US adults live with a smoking-related disease. Cigarette smoking can increase the risk of chronic disease and subsequent complications and can lead to overall reduced quality of life.

Hence, there is considerable shift of the country towards the adoption of the Upper Respiratory Tract Disease Treatment market solutions. The growing awareness regarding the treatment and the rising disposable income, especially in emerging economies, are expected to drive the industry growth.

Market Players Outlook

The major companies serving the upper respiratory tract disease treatment market include: AbbVie Inc., GlaxoSmithKline plc, Johnson & Johnson Pvt. Ltd., Merck & Co., Inc., Novartis AG, Takeda Pharmaceutical Company Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2022, Pfizer Inc. and ReViral Ltd. announced that the two companies have entered into a binding agreement under which Pfizer will acquire ReViral. ReViral is a clinical-stage biopharmaceutical company with a focus on finding, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV).

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global upper respiratory tract disease treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. F. Hoffmann-La Roche Ltd
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Pfizer Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Teva Pharmaceutical Industries Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Upper respiratory tract disease Treatment Market by Category
    • 4.1.1. OTC
    • 4.1.2. Prescription
  • 4.2. Global Upper respiratory tract disease Treatment Market by Treatment
    • 4.2.1. Topical treatment
    • 4.2.2. Cough Suppressant
    • 4.2.3. Nasal Decongestant
    • 4.2.4. Others (Antihistamines, Guaifenesin, and Cromolyn)
  • 4.3. Global Upper respiratory tract disease Treatment Market by Drug class
    • 4.3.1. NSAID
    • 4.3.2. Antibiotics
    • 4.3.3. Others (Ibuprofen)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Alcon, Inc.
  • 6.2. AstraZeneca Plc
  • 6.3. Cipla Limited
  • 6.4. CSL Ltd.
  • 6.5. Dr. Reddy's Laboratories Ltd.
  • 6.6. F. Hoffmann-La Roche Ltd
  • 6.7. GlaxoSmithKline plc
  • 6.8. Lupin Limited
  • 6.9. Market positioning of vendors
  • 6.10. Merck & Co., Inc.
  • 6.11. Novartis AG
  • 6.12. Regeneron Pharmaceuticals Inc.
  • 6.13. Sandoz, Inc.
  • 6.14. Sanofi
  • 6.15. Teva Pharmaceutical Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 2. GLOBAL OTC FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL PRESCRIPTION UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 5. GLOBAL TOPICAL TREATMENT FOR UPPER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 6. GLOBAL COUGH SUPPRESSANT UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 7. GLOBAL NASAL DECONGESTANT UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 8. GLOBAL OTHER TREATMENT FOR UPPER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 9. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 10. GLOBAL NSAID FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 11. GLOBAL ANTIBIOTICS FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT FOR AUTOMOTIVE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 12. GLOBAL OTHER DRUGS FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT FOR HEALTHCARE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 13. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. NORTH AMERICAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 15. NORTH AMERICAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 18. EUROPEAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. EUROPEAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 20. EUROPEAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 21. EUROPEAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 22. ASIA- PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 23. ASIA- PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 24. ASIA- PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 26. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY CATEGORY, 2022 VS 2030 (%)
  • 2. GLOBAL OTC FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL PRESCRIPTION FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY TREATMENT, 2022 VS 2030 (%)
  • 5. GLOBAL TOPICAL TREATMENT FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL COUGH SUPPRESSANT UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL NASAL DECONGESTANT UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL OTHER TREATMENTS FOR UPPER RESPIRATORY TRACT DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 10. GLOBAL NSAID FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT ON BFSI MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL ANTIBIOTICS FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL OTHER DRUGS FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. US UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 15. CANADA UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. UK UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. FRANCE UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. GERMANY UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. ITALY UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. SPAIN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. REST OF EUROPE UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. INDIA UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. CHINA UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. JAPAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. SOUTH KOREA UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. REST OF ASIA-PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)